Houston Research Institute | Houston, TX logo

Houston Research Institute | Houston, TX

Research site
About
Houston Research Institute is dedicated to conducting clinical trials in the areas of Hepatology and Gastroenterology, with a special focus on fatty liver disease. We pride ourselves on conducting high quality research as a complement to the medical care that our volunteers receive from their routine care center.
Location
1155 Dairy Ashford Road Suite 200, Houston, Texas, United States of America
Site insights

Top conditions

Fatty Liver (7 trials)

Non-alcoholic Fatty Liver Disease (7 trials)

Liver Diseases (2 trials)

Fibrosis (2 trials)

Overweight (1 trial)

Top treatments

Resmetirom
TERN-501
HU6
Semaglutide
Lanifibranor
Survodutide
TERN-101
Cilofexor
MK-6024-013
Efinopegdutide

Data sourced from clinicaltrials.gov

Contact this site

Kira Harris

Verified by this site

Trials

8 of 9
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Enrolling
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Placebo
Drug: Semaglutide

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.

Enrolling
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Enrolling
Fatty Liver
Nonalcoholic Steatohepatitis
Other: Placebo
Drug: HU6

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (1 trial)

I

Inventiva Pharma (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems